HER2 Testing in Gastric Cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Advances in Anatomic Pathology

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PAP.0b013e3182026d72PMID 21169738
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics

  2011cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Targeted HER2 Treatment in Advanced Gastric Cancer

  2010cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

  2010cited by this paper
• Clinical practice patterns and cost‐effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

  2010cited by this paper
• HER-2 amplification is highly homogenous in gastric cancer.

  2010cited by this paper
• Trastuzumab in gastric cancer.

  2010cited by this paper
• Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

  2010cited by this paper
• HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series

  2010cited by this paper
• The HER2 testing conundrum

  2010cited by this paper
• Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.

  2009cited by this paper
• Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

  2009cited by this paper
• Gastric cancer.

  2009cited by this paper
• Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Trastuzumab for gastric cancer

  2009cited by this paper
• Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

  2009cited by this paper
• Assessment of a HER2 scoring system for gastric cancer: results from a validation study

  2008influential reference
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus

  2007cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007cited by this paper
• Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models

  2007cited by this paper
• Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

  2006cited by this paper
• HER‐2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

  2006cited by this paper
• Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.

  2005cited by this paper
• The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

  2005influential reference
• A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements

  2004cited by this paper
• Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.

  2004cited by this paper
• HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

  2004cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• [Gastric cancer].

  1996cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies.

  1992cited by this paper
• Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.

  1991cited by this paper
• Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer.

  1991cited by this paper
• Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification.

  1990cited by this paper
• Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

  1986cited by this paper
• Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line

  1986cited by this paper
• Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

  1986cited by this paper
• Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas.

  1986cited by this paper
• Hæmolytic Disease of the New-Born

  1958cited by this paper

• Combined COX-2 and HER-2 Biomarker Profiling to Predict Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer

  2026cites this paper
• Development of Treatment Strategies for Advanced HER2-positive Gastric Cancer: Insights from Clinical Trials.

  2025cites this paper
• Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos

  2025cites this paper
• Thrombospondin-4 from Cancer-associated Fibroblasts Downregulates ERBB2 Expression in Gastric Cancer Cells.

  2025cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• Concordance of HER2 Expression in Paired Primary and Metastatic Sites of Endometrial Serous Carcinoma and the Effect of Intratumoral Heterogeneity

  2024cites this paper
• The Relationship Between HER2 Status Acquired From Pathological Data and Metabolic Parameters From Pre-treatment [18F]FDG PET/CT in Gastric Adenocarcinomas.

  2024cites this paper
• Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: A case report

  2024cites this paper
• Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

  2024cites this paper
• HER2 in uterine serous carcinoma: Current state and clinical perspectives.

  2023cites this paper
• ELITE: Expression deconvoLution using lInear optimizaTion in bulk transcriptomics mixturEs

  2023cites this paper
• Next generation immuno-oncology biomarkers in gastrointestinal cancer: what does the future hold?

  2023cites this paper
• Systemic therapy for gastric cancer: Perioperative strategies and beyond

  2022cites this paper
• Putative Clinical Potential of ERBB2 Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients

  2022cites this paper
• Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers

  2022cites this paper
• MCL1 as putative target in pancreatoblastoma

  2022cites this paper
• Molecular Pathology of Gastric Cancer

  2022cites this paper
• Onkologische Therapieprinzipien beim Magenkarzinom

  2021cites this paper
• Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report.

  2021cites this paper
• Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article

  2021cites this paper
• The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients.

  2021cites this paper
• The unpredictable carbon nanotube biocorona and a functionalization method to prevent protein biofouling

  2021cites this paper
• HER2-targeted therapies in gastric cancer.

  2021cites this paper
• Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm

  2021cites this paper
• HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma

  2021cites this paper
• Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis

  2020cites this paper
• Developing Pathology Measures for the Quality Payment Program-Part II: Overcoming Challenges With Data Capture to Maximize Reimbursement.

  2020cites this paper
• Significance of HER 2/neu in Gastric Adenocarcinomas, A Clinicopathological correlation

  2020cites this paper
• Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.

  2020cites this paper
• HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies

  2020cites this paper
• HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology.

  2020cites this paper
• Significance of EGFR/HER2 Expression and PIK3CA Mutations in Giant Cell Tumour of Bone Development

  2020cites this paper
• Morphological control for molecular testing: a practical approach

  2020cites this paper
• Oncogenes Orchestrate Immunosuppressive Stroma in Gastric Adenocarcinoma

  2020cites this paper
• A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.

  2019cites this paper
• Quantitative Analysis of HER2 Amplification by Droplet Digital PCR in the Follow-Up of Gastric Cancer Patients Being Treated with Trastuzumab after Surgery

  2019cites this paper
• Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

  2019cites this paper
• HER 2 EXPRESSION IN GASTROINTESTINAL TUMOR . A FOCUS ON DIAGNOSTIC ALGORITHM OF HER 2 STATUS FROM GASTRIC TO INTESTINAL CANCER

  2019cites this paper
• HER2 Testing in Gastric and Gastroesophageal Adenocarcinoma—Review and Update

  2019cites this paper
• Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer

  2019influential citation
• Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond.

  2019cites this paper
• Pathological Diagnosis and Classification of Gastric Epithelial Tumours

  2019cites this paper
• Automated detection of the HER2 gene amplification status in Fluorescence in situ hybridization images for the diagnostics of cancer tissues

  2018cites this paper
• Molecular Diagnostics in Esophageal and Gastric Neoplasms: 2018 Update.

  2018cites this paper
• Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis

  2018cites this paper
• Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients.

  2018cites this paper
• miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer

  2018cites this paper
• Development of biomarkers for the risk stratification and targeted therapy of Barrett's oesophagus and oesophageal adenocarcinoma

  2018cites this paper
• A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities

  2018cites this paper
• Strategies in the Era of Personalised Medicine

  2017cites this paper
• Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas

  2017cites this paper
• Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis

  2017cites this paper
• The germline and somatic landscape of Familial Intestinal Gastric Cancer: search for a cause

  2017cites this paper
• Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia

  2017cites this paper
• Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer.

  2017cites this paper
• A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2

  2017cites this paper
• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.

  2017cites this paper
• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

  2017cites this paper
• Associations between serum CA724 and HER2 overexpression among stage II–III resectable gastric cancer patients: an observational study

  2016cites this paper
• HER 2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Guideline

  2016cites this paper
• HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

  2016cites this paper
• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

  2016cites this paper
• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

  2016cites this paper
• Profile of HER2 +ve Gastric Cancers in Brunei Darussalam.

  2016cites this paper
• Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab

  2016cites this paper
• HER2 testing in gastric cancer: An update.

  2016cites this paper
• Overview of Predictive Biomarkers and Integration of IHC into Molecular Pathology

  2015cites this paper
• Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study

  2015cites this paper
• Gastric Cancer: New Drugs - New Strategies

  2015cites this paper
• The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer

  2015cites this paper
• HER2 assessment by silver in situ hybridization: where are we now?

  2015cites this paper
• HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach

  2015cites this paper
• Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer

  2015cites this paper
• Human Epidermal Growth Factor Receptor Expression in Colorectal Cancer and Its Relationship with Clinicopathological Characteristics

  2015cites this paper
• Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models

  2015influential citation
• Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer

  2015cites this paper
• Prognostıc Value of Increased her2 Expression in Cancers of Pancreas and Biliary Tree

  2015cites this paper
• Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis

  2015cites this paper
• Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.

  2015cites this paper
• Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers

  2015cites this paper
• Bile acid induces MUC2 expression and inhibits tumor invasion in gastric carcinomas

  2015cites this paper
• HER2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible?

  2015cites this paper
• Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.

  2015cites this paper
• Immunohistochemistry as a Surrogate for Molecular Testing: A Review

  2015cites this paper
• A novel gene–protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity

  2015cites this paper
• A study of the incidence and prognostic value of HER-2 overexpression in patients with gastric adenocarcinoma in Odisha

  2015cites this paper
• HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.

  2015cites this paper
• Select biomarkers for tumors of the gastrointestinal tract: present and future.

  2015influential citation
• Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction.

  2015cites this paper
• In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma.

  2015cites this paper
• HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria

  2015cites this paper
• Gastrointestinal and Pancreatobiliary Tumors

  2015cites this paper
• A Genomics and Mathematical Modeling Approach for the Study of Helicobacter Pylori associated Gastritis and Gastric Cancer

  2015cites this paper
• Expression of CDX-2 and ALK in primary gastric carcinoma: correlation with Her-2/neu status and prognostic factors

  2015cites this paper
• Application of immunohistochemistry in gastrointestinal and liver neoplasms: new markers and evolving practice.

  2015cites this paper
• HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance

  2014cites this paper
• Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis

  2014cites this paper
• Overexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer

  2014cites this paper
• MICHAEL SAPATEIRO LUÍS

  2014influential citation
• Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer

  2014cites this paper